Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
Accredo Health signs pharmacy agreement for Flolan
May 18th, 2006
Accredo Health Group, Inc., announced an exclusive 5-year agreement as the sole specialty pharmacy for Flolan (epoprostenol sodium), a medication prescribed to treat pulmonary arterial hypertension (PAH). Financial terms of the agreement, which were effective April 1, were not disclosed. "This relationship ensures that patients with pulmonary arterial hypertension - a debilitating condition requiring precise, uninterrupted around-the-clock clinical management - receive this crucial medication through best-in-class specialty pharmacy services provided by Accredo's highly trained pharmacists and nurses," said Tim Wentworth, president and CEO,...
Source: Biotech Business Week (2006-05-18)
|
